SureTrader Stock Hero Advertisement SureTrader SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Sunshine Biopharma Inc. (SBFM)

Add SBFM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BooDog, Gordon Buffett
Search This Board:
Last Post: 5/23/2015 11:50:30 AM - Followers: 169 - Board type: Free - Posts Today: 0




"The Future Of Medicine"


Topoisomerase II is an enzyme that aggressive cancer cells make too much of. When the cell is able to make a lot of the Topoisomerase II 
enzyme, it becomes able to proliferate and metastasize; so, if you can inhibit or destroy the activity of Topoisomerase II, you would then be 
able to prevent cancer cells from spreading. 


Our  Proprietary Technology

Our licensor, Advanomics Corporation, has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a perfect diester isostere.  This technology allows us to create a large variety of therapeutic compounds that are completely stable and often more active than the original drugs.  This unique capability allowed us to create our Lead Compound, Adva-27a, an effective and highly specific Topoisomerase II (Top2) Inhibitor. 

Our Carbon-Difluoride Technology is covered by issued and pending patents filed under PCT/FR2003/002330 and PCT/FR2007/000697


Adva-27a is 16-times more effective at killing multidrug resistant  breast cancer cells than Etoposide, the drug currently in use.

Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.

Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies.

Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.

Adva-27a is an excellent inhibitor of Topoisomerase ll with an IC50 of only 13.7 micromolar.

Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats

Adva-27a's initial indication will be multidrug resistant breast cancer for which there are little or no treatment options





Our Published Data show that Adva-27a is a true Topoisomerase ll Inhibitor and is significantly more effevtive at killing aggressive cancer cells than Etoposide, the current drug of choice.

Check out SBFM's drug Adva-27a (27a) vs the leading chem drug Etoposide (2) - results are better in every category except two. And in the multi drug resistance breast cancer category (MCF7R) it's over 3x more effective. 

Unique Features of Adva-27a  

* Adva-27a can be taken orally.
* Adva-27a is not a so-called me-too drug; our technology is unique. Adva-27a will be the only Topoisomerase ll Inhibitor on the Market.
* Adva-27a's initial indication will be multi-drug resistant breast cancer. Adva-27a can be used to treat other Top2 Positive Cancer Types (Prostate, Colon, Lung, Stomach, Ovarian).

The U.S. Food and Drug Administration's (FDA) approval process is likely to be granted fast-track designation since Adva-27a has the potential to help terminally ill patients with no other therapy options and can be used to treat multiple cancer types. As a result of its unique capabilities, versatility and lack of competition, Sunshine Biopharma's Lead Compound could significantly exceed the typical Revenues generated from anti-cancer drugs, which in general reach $1 Billion in annual sales within two or three years of FDA Approval.

Sunshine Biopharma Drug Pipeline

Adva-27a - Completed Preclinicals
Compound for Small-Cell Lung Cancer - In Preclinical Studies
A Third RNAi-Based Drug

November 19, 2014
Montreal, Quebec, Canada -- (Marketwire) -- Sunshine Biopharma Inc. (OTCQB: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today an agreement with Lonza, a leading development and manufacturing company, for the manufacture of its anti-cancer drug, Adva-27a.  Lonza’s expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients, was an ideal fit for Sunshine’s Adva-27a.  Lonza’s manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialization.  Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.
“We are delighted to have a global leader like Lonza as our manufacturing partner,” said Dr. Steve N. Slilaty, President and CEO of Sunshine Biopharma.  “We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing and recent fund raising efforts.”
“We are very excited to be working with Sunshine Biopharma on the development of their promising anti-cancer compound”, said James Leresche, Ph.D., Head of Lonza’s Chemical Development Services. “This development project is an example of Lonza’s support and commitment to emerging companies with innovative and potentially life-saving treatments like Adva-27a.”
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma & Biotech and Specialty Ingredients. Further information can be found at
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a Topoisomerase II inhibitor, small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).  Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.  The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information:
Sunshine Biopharma Media Contacts:
Renmark Financial Communications Inc.
Robert Thaemlitz:
Joshua Ciarrocca:
Tel.: (416) 644-2020 or (514) 939-3989
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464,
Lonza Media Contacts:
Colleen Floreck, +1 201 316 9290,
Constance Ward, +41 61 316 8840,
Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.

Nansha China

Visp Switzerland

SBFM SEC Filings

Avastin Ousted By FDA For Breast Cancer, Sunshine Biopharma Gears-Up For Clinicals

We were incorporated in the State of Colorado on August 31, 2006 under the name “Mountain West Business Solutions, Inc.”  During our fiscal year ended July 31, 2009 our business was to provide management consulting with regard to accounting, computer and general business issues for small and home-office based companies.  Effective October 15, 2009, we executed an agreement to acquire Sunshine Biopharma, Inc., a Colorado corporation (“SBI”), in exchange for the issuance of 21,962,000 shares of our Common Stock and 850,000 shares of Convertible Preferred Stock, each convertible into twenty (20) shares of our Common Stock (the “Agreement”).  As a result of this transaction our officers and directors resigned their positions with us and were replaced by our current management.  Following completion of this transaction we changed our name to “Sunshine Biopharma, Inc.”.  On December 21, 2011, Advanomics Corporation, a privately held Canadian company (“Advanomics”), and our licensor, exercised its right to convert the 850,000 shares of Series “A” Preferred Stock it held in our Company into 17,000,000 shares of Common Stock.

Intellectual Property

We are the exclusive licensee for the U.S. territory of Advanomics Corporation’s Adva-27a which is covered by international patent applications filed on April 27, 2007 (PCT/FR2007/000697).  These patent applications, which are now issued in Europe and the United States (US 8,236,935) and are still pending elsewhere around the world, were originally owned by Institut National des Sciences Appliquées de Rouen (France) and have recently been purchased by Advanomics Corporation.  On January 14, 2013, Advanomics Corporation filed a new patent application covering Adva-27a manufacturing processes as well as new Adva-27a derivatives and compositions.
Advanomics Corporation, the Parent Company of Sunshine Biopharma

Head Office:

Advanomics Corporation

2015 Peel Street
5th Floor
Montreal, Quebec H3A 1T8

Tel: 514-764-9698
Fax: 514-764-9699

Sunshine Biopharma Media Contacts:
Renmark Financial Communications Inc.
Robert Thaemlitz:
Joshua Ciarrocca:
Tel.: (416) 644-2020 or (514) 939-3989
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464,

Product Pipeline

Our product pipeline is comprised of the following anti-tumor compounds:


Entering Phase I later this year (Lead Compound)



RNAi Anti-Cancer drug candidate
Soon to enter animal studies phase



Currently in preclinical phase


SBFM Share Structure

From and SEC filings
The number of shares of the registrant’s only class of common stock issued and outstanding as of November 10, 2014, was 68,911,041 shares.

Authorized Shares 200,000,000 a/o Dec 31, 2011

31.5 million held by Steve Slilaty, CEO

SBFM Transfer Agent
Corporate Stock Transfer
3200 Cherry Creek Dr. South
Suite 430
Denver, CO 80209
(303) 282 - 4800 p
(303) 282 -  5800 f

Sunshine Biopharma Inc.
2015 Peel Street
5th Floor
Montreal, Quebec H3A 1T8
Tel: 514-764-9698
Fax: 514-764-9699






  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
SBFM News: Quarterly Report (10-q) 05/07/2015 04:52:00 PM
SBFM News: CapRock Research Issues Analyst Report on Avra, Inc. (OTCQB: AVRN): Pioneering Product Innovation in Growing Bitcoin Market 04/08/2015 08:00:00 AM
SBFM News: Annual Report (10-k) 03/11/2015 04:28:45 PM
SBFM News: Current Report Filing (8-k) 02/24/2015 12:44:31 PM
SBFM News: Statement of Changes in Beneficial Ownership (4) 01/22/2015 11:49:09 AM
#18925  Sticky Note All they are saying is NOISE. Clueless BooDog 02/10/15 06:05:42 AM
#11692  Sticky Note Please stay on topic. The only topic to IH Admin [Dan] 10/09/13 10:52:01 AM
#20006   Any chance this year we will have some vip1999 05/23/15 11:50:30 AM
#20005   Ceo crap head slilaty is a scam artist,he Cash Monster 05/20/15 09:56:22 AM
#20004   The raging buy orders for this stock appear reportmyabuse 05/19/15 04:15:18 PM
#20003   more like cardiac arrest imo Kalinn 05/19/15 12:10:21 PM
#20002   yeah what a waste of keyboarding! could have Kalinn 05/19/15 12:09:44 PM
#20001   you made post # 20,000! The highlight of BooDog 05/19/15 11:59:58 AM
#20000   I don't think Steve is doing anything really, Kalinn 05/19/15 11:54:01 AM
#19999   Steve is still trying to fill the subscriptions BooDog 05/19/15 07:36:37 AM
#19998   Zero volume? Must be halted for big news! Lol. reportmyabuse 05/18/15 05:03:49 PM
#19997   if they keep diluting the pps will be Kalinn 05/14/15 07:23:38 PM
#19996   Darn. I guess the only hope is this reportmyabuse 05/14/15 02:36:54 PM
#19995   30$? you see these three amateurs running a Kalinn 05/14/15 02:17:11 PM
#19994   Yeah. So true, so true. But seriously, we're reportmyabuse 05/14/15 01:21:08 PM
#19993   only way to find out is a shareholders Kalinn 05/13/15 07:22:46 PM
#19992   Does that qualify as "administrative expenses" nowadays? I'm reportmyabuse 05/13/15 06:12:48 PM
#19991   so long as Camille sticks around as CFO Kalinn 05/13/15 03:42:34 PM
#19990   It's either dishonesty or incompetency that's torpedoed this Kalinn 05/13/15 03:33:10 PM
#19989   ... and hopefully not a new 2016 bmw Kalinn 05/13/15 03:23:17 PM
#19988   Let's hope the money being raised is actually reportmyabuse 05/13/15 02:17:01 PM
#19987   Haven't been spending much time on this one BooDog 05/12/15 09:12:46 PM
#19986   Share count still has to increase from 117MM Kalinn 05/12/15 08:37:41 PM
#19985   I hadn't noticed that the number of outstanding reportmyabuse 05/12/15 06:06:32 PM
#19984   Everyone knows slilaty ceo is a scam artist Cash Monster 05/07/15 07:22:49 PM
#19983   The ceo slilaty dumped all shares and drives Cash Monster 05/07/15 07:20:47 PM
#19982   The crap head turd slilaty screwed all shareholders Cash Monster 05/07/15 07:14:46 PM
#19981   MARCH 24 2015.... SUNSHINE BIOPHARMA ANNOUNCES ISSUANCE Kalinn 05/06/15 09:05:03 PM
#19980   that was probably merzoukkini's form of remuneration as Kalinn 05/06/15 08:14:34 PM
#19979   Seems stuck at .04 , common slap the reginaliberta 05/06/15 07:24:59 PM
#19978   Guys we got 50million shares in the float. Cash Monster 05/06/15 06:55:48 PM
#19977   You want news,ceo the turd slilaty diluted this Cash Monster 05/06/15 06:48:52 PM
#19976   Pass the gravy please.. Cash Monster 05/06/15 06:44:36 PM
#19975   Better call him quickly,cant count on the useless Cash Monster 05/06/15 05:53:46 PM
#19973   WE WANT THE NEWS ON BREAST CANCER CURE ADVA-27A Angel21stCentury 05/06/15 05:40:24 AM
#19972   Its all crap till now,ceo slilaty never materialized Cash Monster 05/05/15 10:01:58 PM
#19971   Ceo slilaty has news for all shareholders Cash Monster 05/05/15 09:56:41 PM
#19970   Wait until the kid buys out everyone Cash Monster 05/05/15 09:52:47 PM
#19968   agreed nothing to look forward to Armani 05/05/15 08:48:08 PM
#19967   dunno... but Q3 is far far away so Kalinn 05/05/15 08:37:14 PM
#19966   what about the shares he sold tho Armani 05/05/15 08:18:35 PM
#19965   Buy till .05 its a great buy Cash Monster 05/05/15 08:13:28 PM
#19964   TEXAS WILL MAKE THEM ALL DANCE$$$$ Angel21stCentury 05/05/15 07:27:10 PM
#19963   TAKE OUT THE NEWS ON THE CURE TO Angel21stCentury 05/05/15 07:23:33 PM
#19962   HANG ON TO YOUR DIRTY UNDERWEARS FOLKS,HERE COMES ADVA-27A Angel21stCentury 05/05/15 07:21:38 PM
#19961   Process validation is defined as the collection and Kalinn 05/05/15 02:05:39 PM
#19960   "Lonza has deferred the $385,000 payment until the Kalinn 05/05/15 01:53:42 PM
#19959   Call the bombaykid Cash Monster 05/05/15 08:12:34 AM
#19958   Get the volume back again and it could BooDog 05/05/15 07:05:06 AM
#19957   Its a breakout from the toilet bowl after Cash Monster 05/05/15 06:35:23 AM
#19956   read a chart 05 break is breakout Armani 05/04/15 09:48:06 AM
#19955   Slilaty has nothing, he lied to all and Cash Monster 05/03/15 08:24:47 PM